» Articles » PMID: 35249546

Haematological Consequences of Acute Uncomplicated Falciparum Malaria: a WorldWide Antimalarial Resistance Network Pooled Analysis of Individual Patient Data

Overview
Journal BMC Med
Publisher Biomed Central
Specialty General Medicine
Date 2022 Mar 7
PMID 35249546
Affiliations
Soon will be listed here.
Abstract

Background: Plasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia.

Methods: Individual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin < 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall ≥ 25% at day 3 and day 7.

Results: A total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0-19.7 g/dL) in Africa, 11.6 g/dL (range 5.0-20.0 g/dL) in Asia and 12.3 g/dL (range 6.9-17.9 g/dL) in South America. Moderately severe anaemia (Hb < 7g/dl) was present in 8.4% (4284/50,859) of patients from Africa, 3.3% (606/18,451) from Asia and 0.1% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age < 1 compared to ≥ 12 years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39-3.05], p < 0.001).

Conclusions: In patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.

Citing Articles

Characterisation of populations at risk of sub-optimal dosing of artemisinin-based combination therapy in Africa.

Takyi A, Carrara V, Dahal P, Przybylska M, Harriss E, Insaidoo G PLOS Glob Public Health. 2023; 3(12):e0002059.

PMID: 38039291 PMC: 10691722. DOI: 10.1371/journal.pgph.0002059.


Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.

Thriemer K, Degaga T, Christian M, Alam M, Rajasekhar M, Ley B Lancet. 2023; 402(10417):2101-2110.

PMID: 37979594 PMC: 10714037. DOI: 10.1016/S0140-6736(23)01553-2.


Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo.

Onyamboko M, Olupot-Olupot P, Were W, Namayanja C, Onyas P, Titin H BMC Med. 2023; 21(1):397.

PMID: 37858129 PMC: 10588240. DOI: 10.1186/s12916-023-03105-0.


Variability in white blood cell count during uncomplicated malaria and implications for parasite density estimation: a WorldWide Antimalarial Resistance Network individual patient data meta-analysis.

Malar J. 2023; 22(1):174.

PMID: 37280686 PMC: 10243075. DOI: 10.1186/s12936-023-04583-6.


Pathogenicity and virulence of malaria: Sticky problems and tricky solutions.

Walker I, Rogerson S Virulence. 2022; 14(1):2150456.

PMID: 36419237 PMC: 9815252. DOI: 10.1080/21505594.2022.2150456.


References
1.
Yeka A, Banek K, Bakyaita N, Staedke S, Kamya M, Talisuna A . Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med. 2005; 2(7):e190. PMC: 1181876. DOI: 10.1371/journal.pmed.0020190. View

2.
Premji Z, Umeh R, Owusu-Agyei S, Esamai F, Ezedinachi E, Oguche S . Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One. 2009; 4(8):e6682. PMC: 2724683. DOI: 10.1371/journal.pone.0006682. View

3.
Smithuis F, Kyaw M, Phe O, Aye K, Htet L, Barends M . Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet. 2006; 367(9528):2075-85. DOI: 10.1016/S0140-6736(06)68931-9. View

4.
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo J . Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am J Trop Med Hyg. 2005; 73(5):826-32. View

5.
Jullien V, Valecha N, Srivastava B, Sharma B, Kiechel J . Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria. Malar J. 2014; 13:187. PMC: 4046089. DOI: 10.1186/1475-2875-13-187. View